Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Classical hematology 1

Conditions

Renal Insufficiency, Chronic 1Neoplasms 1Kidney Failure, Chronic 1Anemia 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Completed × peginesatide × Clear all
NCT00097747 2012-12-21

Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers

Affymax

Phase 1 Completed
28 enrolled
Classical hematologyGenitourinary

Anemia, Kidney Failure, Chronic, Neoplasms, Renal Insufficiency, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡